Macrophages form a major component of the leukocyte infiltrate in solid tumors and it has become increasingly clear that tumor-associated macrophages (TAMs) have tumor-promoting effects within the stroma [1] . Renal cell carcinoma (RCC) solid tumors are comprised of a heterogeneous microenvironment of both malignant and normal stromal cells containing large numbers of macrophages [2] .
U937 cells poorly reflect the situation in patient tumors. In future studies, the use of patient-derived TAMs from RCC cancer patients would be an alternative approach to address the role of TAMs in RCC in an in vitro setting.
To support their findings, the authors performed immunohistochemical staining of CCR6 and CD68 in 42 RCC tissue samples and reported no association between CCR6 and CD68 positive tissues. CCL20 staining was not performed which would be necessary to identify potential overlap and correlation of TAM and CCL20 tissue distribution. In addition, the data do not address the question of whether TAMs are the major stromal source of CCL20 in RCC patients, which could be examined by isolating cancer cells, macrophages, infiltrating leukocytes and cancer associated fibroblasts from patients followed by measurement of CCL20 secretion in the cultures. Consequently, the co-culture data reported in this study are not supported by patient data.
It would also be better to stain patient tissues with M1 and M2 markers in addition to the general macrophage marker CD68. In line with this suggestion, a previous study analyzed the presence of M1 and M2 macrophages in 185 RCC patients using histological techniques [6] . Using CD68 as a pan-macrophage marker, CD11c for M1 and CD206 as a M2-marker revealed that CD68 alone has a poor predictive value, whereas low CD11c and high CD206 expression as single variables correlated with reduced survival, whereas patients with high CD11c and low CD206 expression had the best survival prognosis [6] . In this context, it should be noted that CD68 was not needed in this analysis. In light of these findings, it is not surprising that CD68 staining did not result in any additional useful knowledge in the present study and underlines the necessity of a complex analysis, using markers for M1, M2 and TAM phenotypes.
Given the important role of TAMs in the progression of RCC and the reported overexpression of CCR6 by cancer cells and aberrant signaling by its ligand CCL20 in many cancer types including colorectal, pancreatic and melanoma solid tumors [8] [9] [10] [11] as well as the development of anti-cancer therapeutics inhibiting CCR6-CCL20 activity [12] , investigation of the involvement and mechanisms of the CCL20-CCR6 axis contributing to the development and progression of renal cell cancer is a worthwhile undertaking.
